EGRX - Eagle Pharmaceuticals (EGRX) Shares Crash After CEO Tarriff Resigns and Disclosing Non-Compliance with Nasdaq - Hagens Berman | Benzinga
SAN FRANCISCO, Dec. 04, 2023 (GLOBE NEWSWIRE) -- Hagens Berman urges Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) investors who suffered substantial losses to submit your losses now.
| Visit: www.hbsslaw.com/investor-fraud/EGRX |
| Contact An Attorney Now: |
| EGRX@hbsslaw.com |
| 844-916-0895 |
Eagle Pharmaceuticals, Inc. (EGRX) Investigation:
"The investigation focuses on the propriety of Eagle Pharmaceuticals revenue recognition practices and the sufficiency of its internal controls over financial reporting," said Reed Kathrein, the Hagens Berman partner leading the investigation.
On Nov. 9, 2023, Eagle announced that it would not timely file its financial report for the quarter ended Sept. 30, 2023. Eagle said "[t]he Company is unable to file its Form 10-Q within the prescribed time period without unreasonable effort or expense primarily because it requires additional time to complete its ...
EGRX) Shares Crash After CEO Tarriff Resigns and Disclosing Non-Compliance with Nasdaq - Hagens Berman>Full story available on Benzinga.com